Lexaria Bioscience (LEXX) Performance Overview
- Current Share Price: USD 2.82
- 24‑Hour Trading Activity: Up 6.42 % as of 06:52 AM Central Europe, Thursday 22 January 2027.
- Shares Outstanding: 1.7 million
- Market Capitalisation: USD 4.4 million
- 24‑Hour Trading Volume: USD 80.9 k
Historical Context
- Month‑End Change: Down 12.42 % since the previous month‑end.
- 200‑Day Simple Moving Average: USD 9.23.
- 52‑Week High: USD 21.60 (recorded 12 December 2025).
- 52‑Week Low: USD 2.43 (recorded 19 October 2026).
Comparative 24‑Hour Performance
| Company | Ticker | 24‑Hour Change | Current Price | Market Capitalisation | Notes |
|---|---|---|---|---|---|
| Zimtu Capital | ZC.V | 0 % | CAD 0.43 | CAD 7.4 million | P/E ratio 0.38 |
| Tsodilo | TSD.V | 0 % | CAD 0.11 | CAD 7.3 million | — |
| Golden Cross | AUX.V | -4.76 % | CAD 0.10 | CAD 7.3 million | — |
| Eranova Metals | NOVA.V | 0 % | CAD 0.13 | CAD 7.3 million | — |
Company Profile
Lexaria Bioscience Corp. is a health‑care company headquartered in Kelowna, Canada, and listed on the Nasdaq stock exchange. The company specializes in pharmaceutical technology that enhances the delivery of active pharmaceutical ingredients (APIs) through improved ingestion methods. Its solutions are applicable to a range of ingestible formats, including foods, beverages, oral suspensions, tablets, and capsules. Lexaria operates a licensed in‑house research laboratory and maintains a substantial intellectual‑property portfolio. Further details can be found at www.lexariabioscience.com .